Galectin 3 detection method and kit based on spatial proximity chemiluminescence

Through the detection method based on spatial proximity chemiluminescence, the existing galactose lectin 3 detection method has solved the problems of low sensitivity and complex operation, and achieved the detection effect of high sensitivity, high specificity and simple operation.

CN119780444AInactive Publication Date: 2025-04-08CHINA MEDICAL BIOTECHNOLOGY (BEIJING) CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411983015.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-31
Publication Date
2025-04-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing galactose lectin 3 detection methods have problems such as low sensitivity, poor specificity, complex operation, and easy to lead to false positive and false negative results.

Method used

Using a detection method based on spatial proximity chemiluminescence, the sample to be tested, horseradish peroxidase-labeled anti-Gal-3 monoclonal antibody and 9,10-dihydroacridine-labeled anti-Gal-3 monoclonal antibody were mixed to form an antigen and antibody sandwich complex, so that horseradish peroxidase and 9,10-dihydroacridine were space-closed, and luminescence aids and triggers were added to generate chemiluminescence to achieve detection.

Benefits of technology

It realizes galactose lectin 3 detection with high sensitivity, high specificity and easy operation, which reduces detection costs, improves detection efficiency, and has good accuracy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119780444A_ABST
    Figure CN119780444A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological detection, in particular to a method and a kit for detecting galectin 3 based on spatial proximity chemiluminescence. The method comprises the following steps: mixing and reacting a to-be-detected sample, an enzyme marker and a luminous marker to obtain a reactant, adding a luminous auxiliary agent and a triggering agent, and detecting the luminous value of the reactant to obtain the content of the galectin 3 in the to-be-detected sample, the enzyme marker is a first anti-Gal-3 monoclonal antibody marked by horse radish peroxidase, and the luminous marker is a second anti-Gal-3 monoclonal antibody marked by 9, 10-dihydroacridine. The detection method disclosed by the invention is high in sensitivity, good in specificity and good in stability, and is nontoxic and harmless to the environment and a human body; carrier and washing steps are not needed in the detection process, cost is low, efficiency is high, and accuracy is good; the kit has the advantages of few components, simple production process, low production cost and easiness in large-scale production and full-automatic detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, and in particular to a galectin 3 detection method and a kit based on spatial proximity chemiluminescence. Background Art

[0002] Heart failure occurs when the heart's ability to pump blood is no longer enough to keep up with the body's demands, causing blood flow to slow, blood to pool in the veins and lungs (congestion), and / or other changes that may further weaken or stiffen the heart. It can occur in people of any age, even young children (especially those born with heart defects). However, it is more common in older people because they are more likely to have disorders that predispose to heart failure (such as coronary artery disease, which can damage the heart muscle) or to have heart valve disease. Age-related changes in the heart also tend to make the heart work less efficiently.

[0003] The markers for diagnosing heart failure are B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). B-type natriuretic peptide is the most important indicator for diagnosing heart failure, but BNP as a marker for heart failure has the following shortcomings: BNP increases with age; and it is higher in women than in men; acute coronary syndrome, lung disease, chronic renal insufficiency and other diseases can also cause BNP to increase; obese people have lower BNP than non-obese people; there are also other widespread biological variations, etc.

[0004] Galectin (Gal) is a class of animal lectin superfamily and is widely distributed in various animals. Gal-3 is encoded by the LGALS3 gene on human chromosome 14 and is expressed in a variety of cells (such as endothelial cells, epidermal cells, macrophages) and tissues (such as heart, liver, kidney, ovary, etc.). It is mainly composed of two parts: an atypical amino terminus and a carboxyl terminal CRD. The amino terminus of Gal-3 consists of 110 to 130 amino acids. This relatively variable structure is rich in proline-glycine-alanine-tyrosine repeating sequences, followed by a unique short terminus. Myocardial fibrosis and cardiac tissue remodeling are the main pathophysiological mechanisms of heart failure. Gal-3 can mediate the infiltration of macrophages and mast cells into the myocardium, stimulate fibroblast proliferation and fibrosis development, and activate inflammatory responses, leading to ventricular remodeling. Studies have shown that Gal-3 has diagnostic value in acute, chronic and new heart failure, and is closely related to the prognosis of heart failure. In the 2017 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, Gal-3 and soluble ST2 are used as indicators for assessing the prognosis of heart failure (Class II, Grade B). Currently, the common methods for detecting Gal-3 are colloidal gold immunochromatography and enzyme-linked immunosorbent assay.

[0005] Although the colloidal gold method is simple, convenient and fast to operate, it can only perform qualitative or semi-quantitative detection, and has large batch-to-batch differences, low sensitivity and poor stability. The enzyme-linked immunosorbent assay method has complex operation steps, is time-consuming, requires professionals, and has many influencing factors during the operation, which can easily lead to false positive and false negative results. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a method and a kit for detecting galectin 3 based on spatial proximity chemiluminescence.

[0007] The technical solution of the present invention to solve the above technical problems is as follows:

[0008] The present invention provides a method for detecting galectin 3 based on spatial proximity chemiluminescence, wherein a sample to be tested, an enzyme marker, and a luminescent marker are mixed and reacted to obtain a reactant, and then a luminescent auxiliary agent and a triggering agent are added to detect the luminescence value of the reactant to obtain the content of galectin 3 in the sample to be tested;

[0009] Wherein, the enzyme marker is a first anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and the luminescent marker is a second anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine.

[0010] Based on the above technical solution, the present invention can also be improved as follows.

[0011] Furthermore, the luminescence auxiliary agent includes hydrogen peroxide, and the triggering agent includes Tween 20.

[0012] Furthermore, the luminescence value of the reactant is positively correlated with the content of galectin-3 in the sample to be tested.

[0013] Further, the following steps are included:

[0014] S1, preparing the enzyme marker and the luminescent marker respectively;

[0015] S2, preparing the luminescence auxiliary agent and the triggering agent respectively;

[0016] S3, obtaining a standard curve corresponding to the luminescence value and concentration of the galectin-3 calibrator;

[0017] S4. Using the enzyme marker, the luminescent marker, the luminescent auxiliary agent and the trigger agent to detect the sample to be tested, and comparing the luminescent value of the sample to be tested with the standard curve to obtain the content of galectin-3 in the sample to be tested.

[0018] Further, in step S1, the preparation method of the enzyme marker is: mixing the aqueous solution of horseradish peroxidase with sodium periodate and sodium acetate buffer and dialyzing; after adding the carbonate buffer, immediately adding the first anti-Gal-3 monoclonal antibody, stirring at room temperature in the dark; adding sodium borohydride solution and mixing, and placing at 4°C for 2h; using PBS for dialyzing at 4°C to obtain the enzyme marker.

[0019] Furthermore, the mass ratio of the horseradish peroxidase to the first anti-Gal-3 monoclonal antibody is 1:1.

[0020] Further, in step S1, the preparation method of the luminescent marker is: adding sodium borate buffer to the DMF solution of 9,10-dihydroacridine, then adding and diluting the second anti-Gal-3 monoclonal antibody, mixing and standing at room temperature; shaking and mixing at 2-8°C overnight to obtain the luminescent marker.

[0021] Furthermore, the mass ratio of the 9,10-dihydroacridine to the second anti-Gal-3 monoclonal antibody is 4:1.

[0022] Further, in step S3, the standard curve is obtained by using the enzyme marker, the luminescent marker, the luminescent auxiliary agent and the trigger agent to respectively detect multiple concentration gradients of galectin 3 calibrators, and drawing the standard curve according to the luminescence value and concentration of each of the galectin 3 calibrators.

[0023] The present invention also provides a kit for detecting galectin-3, which comprises an enzyme marker, a luminescent marker, a luminescent auxiliary agent and a trigger, wherein the enzyme marker is a first anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and the luminescent marker is a second anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine.

[0024] The beneficial effects of the present invention are:

[0025] (1) The galectin-3 detection method based on spatial proximity chemiluminescence of the present invention comprises reacting a sample to be tested, an anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and an anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine together to form an antigen-antibody sandwich complex, so that the horseradish peroxidase and 9,10-dihydroacridine are spatially close to each other, and after adding a luminescence auxiliary agent and a triggering agent, flash-type chemiluminescence is generated, thereby achieving detection;

[0026] (2) The galectin-3 detection method based on spatial proximity chemiluminescence of the present invention has high sensitivity, good specificity, good stability, and is non-toxic and harmless to the environment and human body;

[0027] (3) The galectin-3 detection method based on spatial proximity chemiluminescence of the present invention does not require a carrier and washing steps during the detection process, which not only reduces the cost of the detection method, but also improves the detection efficiency and has good accuracy;

[0028] (4) The galectin-3 detection method based on spatial proximity chemiluminescence of the present invention is a truly homogeneous reaction, and the detection results are more authentic and reliable;

[0029] (5) A kit for detecting galectin-3 has a small number of components, a simple production process, a low production cost, and is easy to scale up for production and fully automatic detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The present invention is a method for detecting galectin-3 based on spatial proximity chemiluminescence, in Example 3, and a quantitative correlation curve between the detection results of the reagent to be evaluated and the comparison reagent. DETAILED DESCRIPTION

[0031] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples given are only used to explain the present invention and are not used to limit the scope of the present invention.

[0032] The method for detecting galectin 3 based on spatial proximity chemiluminescence of the present invention comprises the following steps: mixing and reacting a sample to be tested, an enzyme marker and a luminescent marker to obtain a reactant, adding a luminescent auxiliary agent and a triggering agent, detecting the luminescent value of the reactant, and obtaining the content of galectin 3 in the sample to be tested; wherein the enzyme marker is a first anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and the luminescent marker is a second anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine.

[0033] The present invention discloses a method for detecting galectin 3 based on spatial proximity chemiluminescence, and adopts spatial proximity chemiluminescence analysis (SPARCL) to detect the concentration of Gal-3. The sample to be tested, the anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase (HRP), and the anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine (Acridan) are reacted together to form an antigen-antibody sandwich complex, so that the horseradish peroxidase and 9,10-dihydroacridine (Acridan) are spatially close to each other, and a luminescent auxiliary agent and a triggering agent containing hydrogen peroxide (H2O2) are added to generate flash-type chemiluminescence, and the luminescent signal can be detected by a chemiluminometer; while the unbound free HRP-labeled antibody and the Acridan-labeled antibody do not emit light. The higher the content of Gal-3 in the sample to be tested, the greater the measured luminescence value (RLU). Therefore, within a certain concentration range, the luminescence value is positively correlated with the sample concentration. By drawing a standard curve with calibrants of known concentrations and their luminescence values, the Gal-3 content in the sample can be calculated based on the luminescence value of the sample.

[0034] The detection method of the present invention is based on spatial proximity chemiluminescence, has high sensitivity, good specificity, good stability, and is non-toxic and harmless to the environment and human body; the detection process does not require a carrier and a washing step, which not only reduces the cost of the detection method, but also improves the detection efficiency and has good accuracy. In addition, the method is a truly homogeneous reaction, and the detection results are more authentic and reliable.

[0035] Preferably, the first anti-Gal-3 monoclonal antibody and the second anti-Gal-3 monoclonal antibody of the present invention are purchased from MedixBiochemica, the clone number of the first anti-Gal-3 monoclonal antibody is B-S43, and the clone number of the second anti-Gal-3 monoclonal antibody is B-E53.

[0036] The method for detecting galectin-3 based on spatial proximity chemiluminescence of the present invention comprises the following steps:

[0037] S1. Prepare enzyme markers and the luminescent markers respectively.

[0038] Preferably, the preparation method of the enzyme marker is: mixing an aqueous solution of horseradish peroxidase with sodium periodate and sodium acetate buffer and dialyzing; after adding carbonate buffer, immediately adding the first anti-Gal-3 monoclonal antibody, stirring at room temperature in the dark; adding sodium borohydride solution and mixing, and placing at 4°C for 2h; dialyzing with PBS at 4°C to obtain the enzyme marker.

[0039] Preferably, the mass ratio of horseradish peroxidase to the first anti-Gal-3 monoclonal antibody is 1:1.

[0040] Preferably, the preparation method of the luminescent marker is: adding sodium borate buffer to a DMF solution of 9,10-dihydroacridine, then adding and diluting a second anti-Gal-3 monoclonal antibody, mixing and standing at room temperature; shaking and mixing at 2-8°C overnight to obtain a luminescent marker.

[0041] Preferably, the mass ratio of 9,10-dihydroacridine to the second anti-Gal-3 monoclonal antibody is 4:1.

[0042] S2. Prepare luminescence auxiliary agent and trigger agent respectively.

[0043] Preferably, the components of the luminescence auxiliary agent include citric acid, sodium citrate, hydrogen peroxide and water.

[0044] Preferably, the triggering agent comprises tris hydrochloride, NaCl, concentrated HCl, Tween 20 and water.

[0045] S3. Obtain a standard curve corresponding to the luminescence value and concentration of the galectin-3 calibrator.

[0046] Preferably, the standard curve is obtained by using an enzyme marker, a luminescent marker, a luminescent auxiliary agent and a trigger to respectively detect multiple concentration gradients of galectin-3 calibrators, and drawing a standard curve according to the luminescent value and concentration of each galectin-3 calibrator.

[0047] Preferably, the calibrator is prepared using potassium dihydrogen phosphate, sodium dihydrogen phosphate dihydrate, Proclin 300, galectin 3 and water.

[0048] Further preferably, the concentration gradient of the calibrator is 0 ng / mL, 5 ng / mL, 25 ng / mL, 150 ng / mL, 750 ng / mL, and 1500 ng / mL.

[0049] S4. Use enzyme markers, luminescent markers, luminescent auxiliary agents and triggering agents to detect the sample to be tested, compare the luminescent value of the sample to be tested with the standard curve, and obtain the content of galectin 3 in the sample to be tested.

[0050] The present invention also provides a galectin 3 detection kit based on spatial proximity chemiluminescence, which includes an enzyme marker, a luminescent marker, a luminescent auxiliary agent and a trigger, wherein the enzyme marker is a first anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and the luminescent marker is a second anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine.

[0051] The kit of the present invention has few components, simple production process, low production cost, and is easy to scale up for production and fully automatic detection.

[0052] The kit of the present invention can be used to detect galectin 3 in a sample. It should be noted that the kit of the present invention may also include reagents for preparing the above-mentioned components and auxiliary reagents that may exist or may be used.

[0053] In the embodiments of the present invention, the sources of various materials are as follows:

[0054] Anti-Gal-3 monoclonal antibodies were purchased from Medix Biochemica, the clone number of the first anti-Gal-3 monoclonal antibody was B-S43, and the clone number of the second anti-Gal-3 monoclonal antibody was B-E53.

[0055] The Gal-3 antigen in the examples was purchased from Wuhan Huamei Biotechnology Co., Ltd., with the catalog number: CSB-EP012887MO.

[0056] Among other reagents, horseradish peroxidase, sodium periodate, sodium borohydride, sodium acetate, sodium carbonate, sodium bicarbonate, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, tris (hydroxymethyl)aminomethane hydrochloride (Tris), hydrochloric acid, citric acid, sodium citrate, glycerol, boric acid, sodium tetraborate, sucrose, aminopyrine, Tween 20, Triton 100, potassium dihydrogen phosphate, hydrogen peroxide, and dimethylformamide were purchased from Sinopharm Chemical Reagent Co., Ltd. Bovine serum albumin, casein, Proclin 300, polyethylene glycol 2000, etc. were purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., and 9, 10-dihydroacridine was purchased from Sichuan Weiqiqi Biotechnology Co., Ltd.

[0057] The instrument is the HomoG 100 fully automatic chemiluminescence analyzer produced by Guangzhou Jinde Biotechnology Co., Ltd.

[0058] Example 1 Preparation of various detection reagents for galectin-3

[0059] (1) Preparation of enzyme marker: Weigh 1 mg HRP and dissolve it in 200 μL distilled water, add 40 μL of freshly prepared 0.1 M sodium periodate, shake and mix at room temperature for 20 min, put the above liquid into a dialysis bag, dialyze it with 1 mM sodium acetate buffer, pH 4.4, at 4°C overnight, add 20 μL of 0.2 M carbonate buffer, pH 9.5, and then immediately add 1 mg of the first anti-Gal-3 monoclonal antibody, gently stir for 2 h at room temperature in the dark, add 10 μL of freshly prepared 4 mg / mL sodium borohydride solution, mix well, and place at 4°C for 2 h. Put the above liquid into a dialysis bag, dialyze it with 0.15 M PBS, pH 7.4, at 4°C overnight, remove the dialysate, add 50% glycerol, and store it at -20°C for later use.

[0060] (2) Preparation of luminescent markers: Dissolve 1 mg of the luminescent substrate Acridan in 500 μL of DMF, take out 41.3 μL, add 708.7 μL of 0.05 M sodium borate buffer, then add 250 μL of anti-Gal-3 (diluted to 1 mg / mL), invert and mix 5 times, let stand at room temperature for 30 min, place the labeled reaction tube on an oscillator and mix overnight at 2-8°C, take out, add 50% glycerol and store in a -20°C refrigerator.

[0061] (3) Luminescence auxiliary agent: Weigh 1.82 g of citric acid and 10.45 g of sodium citrate, dissolve in purified water and make up to 1000 mL, add 0.3 mL of 30% hydrogen peroxide to the buffer solution, mix well and place in a 4°C refrigerator for later use (pack into 10 mL / bottle).

[0062] (4) Trigger: Weigh 6.06 g of Tris and 9 g of NaCl, add appropriate amount of purified water to dissolve, add 2.1 mL of concentrated HCl and 2 mL of Tween 20, mix well and make up to 1000 mL, and place in a 4°C refrigerator for later use.

[0063] Example 2 Preparation of Calibrators

[0064] (1) Calibrator diluent: Weigh 14.1 g potassium dihydrogen phosphate and 3.0 g sodium dihydrogen phosphate dihydrate, add appropriate amount of purified water to dissolve, add 0.5 mL Proclin 300, mix well, add purified water to make up to 1000 mL, and place in a 4°C refrigerator for later use.

[0065] (2) Use the calibration diluent to dilute the Gal-3 antigen to 0 ng / mL, 5 ng / mL, 25 ng / mL, 150 ng / mL, 750 ng / mL, and 1500 ng / mL and place in a 4°C refrigerator for later use.

[0066] Example 3 Detection of samples

[0067] In this embodiment, the kit is used to detect the calibrators and the samples to be tested in Example 2. The kit includes the detection reagent prepared in Example 1.

[0068] The specific detection process is carried out using a chemiluminescent immunoassay analyzer, and the system requires 10 μL of sample for each measurement. The detection process is as follows:

[0069] (1) Preparation before testing: Before testing, all materials required for the test should be prepared and the instruction manual of the chemiluminescent immunoassay analyzer should be carefully read to obtain information such as system operating procedures, sample management, precautions for use, maintenance and care.

[0070] (2) Calibration: Use the kit and calibrator to perform the calibration test. Before starting the kit calibration, the master curve in the 2D barcode of the kit should be scanned and imported into the system.

[0071] The chemiluminescent immunoassay analyzer adjusts the master curve based on the results of the calibration test to obtain the calibration curve of the current system. The instrument operation software has a calibration judgment function to automatically check the validity of the calibration curve. If the calibration fails, the instrument settings, status, location of the calibration (low-value calibration, high-value calibration), validity period, etc. should be considered.

[0072] A valid calibration curve is required before all tests. Recalibration is required in the following situations: when a new batch of reagent kit is used; when the same batch of reagent kit is used on the analyzer for more than 30 days; after instrument maintenance; or when the quality control value is out of the specified range.

[0073] (3) Quality Control: To ensure the reliability of the test results, it is recommended to test the high and low levels of quality control products once every 24 hours. In addition, it is also recommended to perform quality control tests after each calibration test, reagent batch change, maintenance and troubleshooting.

[0074] The test value of the quality control product should be within the specified range. If it exceeds the specified range, the user should check the detection system, such as the location, validity period, storage method, calibration process, instrument performance and status, etc. of the quality control product, and recalibrate if necessary. Sample testing can only be carried out after the quality control is qualified.

[0075] (4) Sample testing: Enter the sample application interface of the instrument and enter the sample number, sample rack number, position number, sample type, remarks and other information according to the test requirements. Select the test item, select the sample type in the item options, and enter the number of repetitions and other information. After preparing the test sample and placing it correctly, click the start button to start the test. The chemiluminescent immunoassay analyzer will perform the following operations in sequence:

[0076] 1. The sample processing system transfers the sample rack to the sample suction position;

[0077] 2. The cuvette loading and dispatching system loads the cuvette from the loading area to the sample loading position;

[0078] 3. The sample injection system completes the sample injection and sample needle cleaning;

[0079] 4. The reagent processing system provides the reagents required for the test, mixes each reagent and sends it to the reagent aspiration position to wait for aspiration;

[0080] 5. The sample adding system completes the dispensing of reagents and the cleaning of reagent needles;

[0081] 6. Mix the reaction mixture with the counter-liquid mixing system and incubate in the reaction plate;

[0082] 7. After the incubation is completed, inject the substrate solution into the substrate system, mix, incubate, and wait for light measurement;

[0083] 8. The light measurement reaction system sends each reaction cup to the signal collection position to collect signals for calculating the luminescence value;

[0084] 9. Calculate the amount of analyte in the sample.

[0085] (5) Calculation: Based on the saved calibration data, the system software uses a weighted four-parameter logarithmic curve (4PLC, Y-weighted) mathematical method to automatically determine the test results of the sample. The result unit is given in the form of pg / mL.

[0086] This example uses the above detection process to test blood samples from 42 patients with myocardial injury (reagent to be evaluated). For these blood samples, this example also uses the Shanghai Zeye Biotechnology Co., Ltd. Galectin 3 (GAL3) detection kit (ELISA method) for detection (comparison reagent), and the specific test results are shown in Table 1.

[0087] Table 1

[0088]

[0089]

[0090] The results of the comparison reagent are used as the horizontal axis, and the results of the reagent to be evaluated are used as the vertical axis. Figure 1 The quantitative correlation curve shown is used to examine the accuracy of the method of this embodiment compared with the comparison method.

[0091] By comparison, the quantitative correlation coefficient R between the detection method of this embodiment and the detection result of the comparison reagent is 2 =0.9952, indicating that the method of the present invention has good accuracy.

[0092] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for detecting galectin-3 based on spatial proximity chemiluminescence, characterized in that: The sample to be tested, the enzyme marker, and the luminescent marker are mixed and reacted to obtain a reactant, and then a luminescent auxiliary agent and a triggering agent are added to detect the luminescence value of the reactant to obtain the content of galectin-3 in the sample to be tested; Wherein, the enzyme marker is a first anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and the luminescent marker is a second anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine.

2. The method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 1, characterized in that: The luminescence auxiliary agent includes hydrogen peroxide, and the trigger agent includes Tween 20.

3. A method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 2, characterized in that: The luminescence value of the reactant is positively correlated with the content of galectin-3 in the sample to be tested.

4. A method for detecting galectin-3 based on spatial proximity chemiluminescence according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1, preparing the enzyme marker and the luminescent marker respectively; S2, preparing the luminescence auxiliary agent and the triggering agent respectively; S3, obtaining a standard curve corresponding to the luminescence value and concentration of the galectin-3 calibrator; S4. Using the enzyme marker, the luminescent marker, the luminescent auxiliary agent and the trigger agent to detect the sample to be tested, and comparing the luminescent value of the sample to be tested with the standard curve to obtain the content of galectin-3 in the sample to be tested.

5. The method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 4, characterized in that: In step S1, the preparation method of the enzyme marker is as follows: mixing the aqueous solution of horseradish peroxidase with sodium periodate and sodium acetate buffer and dialyzing; after adding the carbonate buffer, immediately adding the first anti-Gal-3 monoclonal antibody, stirring at room temperature in the dark; adding the sodium borohydride solution and mixing, and placing at 4°C for 2h; dialyzing with PBS at 4°C to obtain the enzyme marker.

6. The method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 5, characterized in that: The mass ratio of the horseradish peroxidase to the first anti-Gal-3 monoclonal antibody is 1:

1.

7. The method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 4, characterized in that: In step S1, the preparation method of the luminescent marker is: adding sodium borate buffer to the DMF solution of 9,10-dihydroacridine, then adding and diluting the second anti-Gal-3 monoclonal antibody, mixing and standing at room temperature; shaking and mixing at 2-8°C overnight to obtain the luminescent marker.

8. The method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 7, characterized in that: The mass ratio of the 9,10-dihydroacridine to the second anti-Gal-3 monoclonal antibody is 4:

1.

9. The method for detecting galectin-3 based on spatial proximity chemiluminescence according to claim 4, characterized in that: In step S3, the standard curve is obtained by using the enzyme marker, the luminescent marker, the luminescent auxiliary agent and the trigger agent to respectively detect multiple concentration gradients of galectin 3 calibrators, and drawing the standard curve according to the luminescence value and concentration of each of the galectin 3 calibrators.

10. A kit for detecting galectin-3, characterized in that: The kit comprises an enzyme marker, a luminescent marker, a luminescent auxiliary agent and a triggering agent. The enzyme marker is a first anti-Gal-3 monoclonal antibody labeled with horseradish peroxidase, and the luminescent marker is a second anti-Gal-3 monoclonal antibody labeled with 9,10-dihydroacridine.

Citation Information

Patent Citations

  • Novel chemical light emitting ezyme immunological analysis method

    CN101051047A

  • Nonseparation assay methods

    CN102175851A

  • Method for detecting cardiac troponin I / T through flash type homogeneous chemiluminescence technology

    CN110031635A

  • Kit for detecting galectin-3 by chemiluminiscence method and use method

    CN111505304A

  • Kit for detecting procalcitonin by spatial proximity chemiluminescence method and detection method and application thereof

    CN113238055A